Clinical Trials Directory

Trials / Completed

CompletedNCT04107259

IRAPe, Irisin and IL-34 in Patients With Type 2 Diabetes

Circulating IRAPe, Irisin and IL-34 in Relation to Insulin Resistance in Patients With Type 2 Diabetes

Status
Completed
Phase
Study type
Observational
Enrollment
120 (actual)
Sponsor
Damanhour University · Academic / Other
Sex
All
Age
35 Years – 65 Years
Healthy volunteers

Summary

Aim: This study aimed to evaluate the role of extracellular part of insulin regulated aminopeptidase (IRAPe), IL-34, Irisin, and Visfatin in the development of insulin resistance in patients with type 2 diabetes mellitus. Methods: parallel study enrolled 60 non-diabetic control subjects and 60 newly-diagnosed type 2 diabetics, matched for age, body mass index and sex ratio.

Detailed description

Aim: This study aimed to evaluate the role of extracellular part of insulin regulated aminopeptidase (IRAPe), IL-34, Irisin, and Visfatin in the development of insulin resistance in patients with type 2 diabetes mellitus. Methods: parallel study enrolled 60 non-diabetic control subjects and 60 newly-diagnosed type 2 diabetics, matched for age, body mass index and sex ratio. Anthropometric parameters, blood glucose, fasting plasma insulin, insulin resistance index (HOMA-IR), IL34, Irisin, IRAPe, Visfatin and glycated hemoglobin were assessed. Conclusion: IL-34 and Visfatin levels were significantly increased, while both Irisin and IRAPe levels were significantly decreased in patients with type 2 diabetes. Theses aforementioned parameters were significantly correlated with insulin resistance. These findings indicate that, IL-34, Irisin and IRAPe may play a vital role in T2DM and in diabetes associated insulin resistance. Additionally, the investigator's findings proposed that, IRAPe may be a useful and direct marker for detection of insulin resistance state.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTBlood sampleTen ml of venous blood was collected from all participants in the early morning after an overnight 12 hour fast by venipuncture of the antecubital vein into sterile tubes. Plasma and sera were separated immediately and were stored at -70 C until biochemical analyses.

Timeline

Start date
2019-01-19
Primary completion
2019-06-30
Completion
2019-07-20
First posted
2019-09-27
Last updated
2020-07-29

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04107259. Inclusion in this directory is not an endorsement.